Unsymmetrical cyclotriazadisulfonamide (CADA) compounds as human CD4 receptor down-modulating agents

Journal of Medicinal Chemistry

Volumn 54, Issue 16, 2011, Pages 5712-5721

  Demillo, Violeta G ^a   Goulinet Mateo, Florian ^a   Kim, Jessica ^a   Schols, Dominique ^b   Vermeire, Kurt ^b   Bell, Thomas W ^a  

^a UNIVERSITY OF NEVADA   (United States)

^b REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CYCLOALKANE DERIVATIVE; CYCLOTRIAZADISULFONAMIDE; IMMUNOMODULATING AGENT; MEMBRANE ANTIGEN; SULFONAMIDE; UNCLASSIFIED DRUG; VGD 010; VGD 011; VGD 012; VGD 013; VGD 014; VGD 015; VGD 016; VGD 017; VGD 018; VGD 019; VGD 020; VGD 021; VGD 022; VGD 023; VGD 024; VGD 025; VGD 028; VGD 029; VGD 038; VGD 039; VGD 048; VGD 049;

ANIMAL CELL; ARTICLE; DRUG POTENCY; DRUG SYNTHESIS; ENTROPY; FLUORESCENCE; HUMAN IMMUNODEFICIENCY VIRUS; IC 50; MOLECULAR INTERACTION; MOLECULAR MODEL; MOLECULAR STABILITY; NONHUMAN; RECEPTOR DOWN REGULATION; STRUCTURE ACTIVITY RELATION; VIRUS INHIBITION;

ANIMALS; ANTI-HIV AGENTS; ANTIGENS, CD4; CHO CELLS; CRICETINAE; CRICETULUS; DOWN-REGULATION; FLOW CYTOMETRY; HETEROCYCLIC COMPOUNDS; HUMANS; LUMINESCENT PROTEINS; MODELS, CHEMICAL; MOLECULAR STRUCTURE; STRUCTURE-ACTIVITY RELATIONSHIP; THERMODYNAMICS;

EID: 80051902523     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm2002603     Document Type: Article

References (53)

1. Littman, D. R. The structure of the CD4 and CD8 genes Annu. Rev. Immunol. 1987, 5, 561-584
2. Janeway, C. A., Jr. The role of CD4 in T-cell activation: accessory molecule or co-receptor? Immunol. Today 1989, 10, 234-238 (Pubitemid 19158895)
3. Ellmeier, W.; Sawada, S.; Littman, D. R. The regulation of CD4 and CD8 coreceptor gene expression during T cell development Annu. Rev. Immunol. 1999, 17, 523-554 (Pubitemid 29241133)
4. Nepom, G. T. Therapy of autoimmune diseases: clinical trials and new biologics Curr. Opin. Immunol. 2002, 14, 812-815 (Pubitemid 35292431)
5. Taylor, P. C. Antibody therapy for rheumatoid arthritis Curr. Opin. Pharmacol. 2003, 3, 323-328 (Pubitemid 36686775)
6. Liu, E.; Moriyama, H.; Paronen, J.; Abiru, N.; Miao, D.; Yu, L.; Taylor, R. M.; Eisenbarth, G. S. Nondepleting anti-CD4 monoclonal antibody prevents diabetes and blocks induction of insulin autoantibodies following insulin peptide B:9-23 immunization in the NOD mouse J. Autoimmun. 2003, 21, 213-219 (Pubitemid 37410110)
7. Hanns-Martin, L. T-cell-activation inhibitors in rheumatoid arthritis BioDrugs 2003, 17, 263-270
8. Kim, Y. H.; Douvic, M.; Obitz, E.; Gniadecki, R.; Iversen, L.; Osterborg, A.; Whittaker, S.; Illidge, T. M.; Schwarz, T.; Kaufmann, R.; Cooper, K.; Knudsen, K. M.; Lisby, S.; Baadsgaard, O.; Knox, S. J. Clinical efficacy of zanolimumab (HuMax-CD4): two phase 2 studies in refractory cutaneous T-cell lymphoma Blood 2007, 109 (11) 4655-4662 (Pubitemid 46827755)
9. Dalgleish, A. G.; Beverly, P. C.; Clapham, P. R.; Crawford, D. H.; Greaves, M. F.; Weiss, R. A. The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus Nature 1984, 312, 763-767 (Pubitemid 15195924)
10. Klatzmann, D.; Champagne, E.; Chamaret, S.; Gruest, J.; Guetard, D.; Hercend, T.; Gluckman, J. C.; Montagnier, L. T-lymphocyte T4 molecule behaves as the receptor for human retrovirus LAV Nature 1984, 312, 767-768 (Pubitemid 15195925)
11. Freeman, M. M.; Seaman, M. S.; Rits-Volloch, S.; Hong, X.; Kao, C. Y.; Ho, D. D.; Chen, B. Crystal structure of HIV-1 primary receptor CD4 in complex with a potent antiviral antibody Structure 2010, 18 (12) 1632-1641
12. Matthias, L. J.; Azimi, I.; Tabrett, C. A.; Hogg, P. J. Reduced monomeric CD4 is the preferred receptor for HIV J. Biol. Chem. 2010, 285 (52) 40793-40799
13. Veiga, A. S.; Santos, N. C.; Castanho, M. A. R. B. An insight on the leading HIV entry inhibitors Recent Pat. Anti-Infect. Drug Discovery 2006, 1, 67-73
14. Esté, J. A.; Telenti, A. HIV entry inhibitors Lancet 2007, 370, 319-328
15. DeClercq, E. The design of drugs for HIV and HCV Nat. Rev. Drug Discovery 2007, 6, 1001-1018
16. Qian, K.; Morris-Natschke, S. L.; Lee, K.-H. HIV entry inhibitors and their potential in HIV Therapy Med. Res. Rev. 2008, 2009 (29) 369-393
17. Reimann, K. A.; Khunkhun, R.; Lin, W.; Gordon, W.; Fung, M. A humanized, nondepleting anti-CD4 antibody that blocks virus entry inhibits virus replication in rhesus monkeys chronically infected with simian immunodeficiency virus AIDS Res. Hum. Retroviruses 2002, 18, 747-755
18. Kuritzkes, D. R.; Jacobsen, J.; Powderly, W. G.; Godofsky, E.; DeJesus, E.; Haas, F.; Reimann, K. A.; Larson, J. L.; Yarbough, P. O.; Curt, V.; Shanahan, W. R., Jr. Antiretroviral activity of the anti-CD4 monoclonal antibody TNX-355 in patients infected with HIV type 1 J. Infect. Dis. 2004, 189, 286-291 (Pubitemid 38147253)
19. Schols, D. HIV co-receptors as targets for antiviral therapy Curr. Top. Med. Chem. 2004, 4, 883-893 (Pubitemid 38854847)
20. Kazmierski, W. M.; Gudmundsson, K. S.; Piscitelli, S. C. Small Molecule CCR5 and CXCR4-Based Viral Entry Inhibitors for Anti-HIV Therapy Currently in Development. In Annual Reports in Medicinal Chemistry; Macor, J. E., Ed.; Academic Press: Amsterdam, 2007; Vol. 42, pp 301-320.
21. Conti, L.; Varano, B.; Gauzzi, M. C.; Matarrese, P.; Federico, M.; Malorni, W.; Belardelli, F.; Gessani, S. Impairment of human immunodeficiency virus type 1 (HIV-1) entry into Jurkat T cells by constitutive expression of the HIV-1 vpr protein: role of CD4 down-modulation J. Virol. 2000, 74, 10207-10211
22. Nokta, M. A.; Li, X. D.; Nichols, J.; Mallen, M.; Pou, A.; Asmuth, D.; Pollard, R. B. Chemokine/CD4 receptor density ratios correlate with HIV replication in lymph node and peripheral blood of HIV-infected individuals AIDS Res. Hum. Retroviruses 2001, 15, 161-169 (Pubitemid 32142290)
23. Xiang, J.; McLinden, J. H.; Rydze, R. A.; Chang, Q.; Kaufman, T. M.; Klinzman, D.; Stapleton, J. T. Viruses within the flaviviridae decrease CD4 expression and inhibit HIV replication in human CD4+ cells J. Immunol. 2009, 183, 7860-7869
24. Lisco, A.; Grivel, J. C.; Biancotto, A.; Vanpouille, C.; Origgi, F.; Malnati, M. S.; Schols, D.; Lusso, P.; Margolis, L. B. Viral interactions in human lymphoid tissue: human herpesvirus 7 suppresses the replication of CCR5-tropic human immunodeficiency virus type 1 via CD4 modulation J. Virol. 2007, 81, 708-717 (Pubitemid 46067897)
25. Vermeire, K.; Bell, T. W.; Choi, H. J.; Jin, Q.; Samala, M. F.; Sodoma, A.; De Clercq, E.; Schols, D. The anti-HIV potency of cyclotriazadisulfonamide analogs is directly correlated with their ability to down-modulate the CD4 receptor Mol. Pharmacol. 2003, 63, 203-210 (Pubitemid 36043824)
26. Beaumier, C. M.; Harris, L. D.; Goldstein, S.; Klatt, N. R.; Whitted, S.; McGinty, J.; Apetrei, C.; Pandrea, I.; Hirsch, V. M.; Brenchley, J. M. CD4 downregulation by memory CD4+ T cells in vivo renders African green monkeys resistant to progressive SIVagm infection Nat. Med. 2009, 15, 879-885
27. Vermeire, K.; Zhang, Y.; Princen, K.; Hatse, S.; Samala, M.; Dey, K.; Choi, H.-J.; Ahn, Y.; Sodoma, A.; Snoeck, R.; Andrei, G.; De Clercq, E.; Bell, T. W.; Schols, D. CADA inhibits human immunodeficiency virus and human herpesvirus 7 replication by down-modulation of the cellular CD4 receptor Virology 2002, 302, 342-353 (Pubitemid 35373862)
28. Vermeire, K.; Princen, K.; Hatse, S.; De Clercq, E.; Dey, K.; Bell, T. W.; Schols, D. CADA, a novel CD4-targeted HIV inhibitor, is synergistic with various anti-HIV drugs in vitro AIDS Res. Hum. Retroviruses 2004, 18, 2115-2125 (Pubitemid 39463676)
29. Vermeire, K.; Schols, D.; Bell, T. W.; Marsh, M. A small-molecule inhibitor of CD4 protein translocation down-modulates the primary HIV receptor. Manuscript under revision.
30. Bell, T. W.; Anugu, S.; Bailey, P.; Catalano, V. J.; Dey, K.; Drew, M. G.; Duffy, N. H.; Jin, Q.; Samala, M. F.; Sodoma, A.; Welch, W. H.; Schols, D.; Vermeire, K. Synthesis and structure-activity relationship studies of CD4 down-modulating cyclotriazadisulfonamide (CADA) analogues J. Med. Chem. 2006, 49, 1291-1312 (Pubitemid 43271884)
31. Vermeire, K.; Lisco, A.; Grivel, J.-C.; Scarbrough, E.; Dey, K.; Duffy, N.; Margolis, L.; Bell, T. W.; Schols, D. Design and cellular kinetics of dansyl-labeled CADA derivatives with anti-HIV and CD4 receptor down-modulating activity Biochem. Pharmacol. 2007, 74, 566-578 (Pubitemid 47042007)
32. Richman, J.; Atkins, T. J. Nitrogen analogs of crown ethers J. Am. Chem. Soc. 1974, 96, 2268-2270
33. Atkins, T. J.; Richman, J. E.; Oettle, W. F. Macrocyclic Polyamines: 1,4,7,10,13,16-Hexaazacyclooctadecane.; Wiley: New York, 1988; pp 652-662.
34. Ali, R.; Anugu, S.; Khan, C.; Demillo, V. G.; Goulinet-Mateo, F.; Lamprecht, K.; Scarbrough, E.; Bell, T. W. Palladium-catalyzed synthesis of 1,5,9-triazacyclododecanes by macrocyclization of disulfonamides with carbonate esters of 2-methylene-1,3-dihydroxypropane. Manuscript in preparation.
35. Olofsen, R. A.; Abott, D. E. Tests of a piperidino mask for the protection of functionalized carbon sites in multistep syntheses J. Org. Chem. 1984, 49, 2795-2799
36. Olofsen, R. A.; Martz., J. T.; Senet, J.-P.; Piteau, M.; Malfroot, T. A new reagent for the selective, high-yield N-dealkylation of tertiary amines: improved synthesis of naltrexone and nalbuphine J. Org. Chem. 1984, 49, 2081-2082
37. Demillo, V. Unsymmetrical Cyclotriazadisulfonamide (CADA) Compounds: Synthesis and CD4 Down-Modulation Potency. Ph.D. Dissertation, University of Nevada, Reno, NV, 2011.
38. Pokhvisneva, G. V.; Luk'yanov, O. A. Synthesis of 2-substituted 1-tosyl-3(1-tosyliminoalkyl)imidazolidines and hexahydropyrimidines Russ. Chem. Bull., Int. Ed. 2006, 55, 903-906
39. Antonopoulou, G.; Magrioti, V.; Stephens, D.; Constantinou-Kokotou, V.; Dennis, E. A.; Kokotos, G. Synthesis of 2-oxoamides based on sulfonamide analogs of amino acids and their activity on phospholipase A2 J. Pept. Sci. 2008, 14, 1111-1120
40. Saab, N. H.; West, E. E.; Bieszk, N. C.; Prews, C. V.; Mank, A. R.; Casero, R. A., Jr.; Woster, P. M. Synthesis and evaluation of unsymmetrically substituted polyamine analogues as modulators of human spermidine/spermine- N -acetyltransferase (SSAT) and as potential antitumor agents J. Med. Chem. 1993, 36, 2998-3004 (Pubitemid 23315404)
41. Yokoshima, S.; Ueda, T.; Kobayashi, S.; Sato, A.; Kuboyama, T.; Tokuyama, H.; Fukuyama, T. Stereocontrolled total synthesis of (+)-vinblastine J. Am. Chem. Soc. 2002, 124, 2137-2139 (Pubitemid 34267098)
42. Osborne, A. R.; Rapoport, T. A.; van den Berg, B. Protein translocation by the Sec61/SecY channel Annu. Rev. Cell Dev. Biol. 2005, 21) 529-550 (Pubitemid 41740645)
43. Garrison, J. L.; Kunkel, E. J.; Hegde, R. S.; Taunton, J. A substrate-specific inhibitor of protein translocation into the endoplasmic reticulum Nature 2005, 436, 287-289
44. Besemer, J.; Harant, H.; Wang, S.; Oberhauser, B.; Marquardt, K.; Foster, C. A.; Schreiner, E. P.; de Vries, J. E.; Dascher-Nadel, C.; Lindley, I. J. D. Selective inhibition of cotranslational translocation of vascular cell adhesion molecule Nature 2005, 436, 290-293 (Pubitemid 41021283)
45. Williams, D. H.; Stephens, E.; OBrien, D. P.; Zhou, M. Understanding noncovalent interactions: ligand binding energy and catalytic efficiency from ligand-induced reductions in motion within receptors and enzymes Angew. Chem., Int. Ed. 2004, 43, 6596-6616 (Pubitemid 40018986)
46. Whitesides, G. M.; Krishnamurthy, V. M. Designing ligands to bind proteins Q. Rev. Biophys. 2005, 38 (4) 385-395 (Pubitemid 44366939)
47. Williams, D. H.; Stephens, E.; Zhou, M. Ligand binding energy and catalytic efficiency from improved packing within receptors and enzymes J. Mol. Biol. 2003, 329, 389-399 (Pubitemid 36561593)
48. Baum, B.; Muley, L.; Smolinski, M.; Heine, A.; Hangauer, D.; Klebe, G. Non-additivity of functional group contributions in protein-ligand binding: a comprehensive study by crystallography and isothermal titration calorimetry J. Mol. Biol. 2010, 397, 1042-1054
49. Hilgeroth, A.; Molnur, J.; De Clercq, E. Using molecular symmetry to form new drugs: hydroxymethyl-substituted 3,9-diazatetraasteranes as the first class of symmetric MDR modulators Angew. Chem., Int. Ed. 2002, 41, 2623-3625
50. Sanmartn, C.; Font, M.; Palop, J. A. Molecular symmetry: a structural property frequently present in new cytotoxic and proapoptotic drugs Mini-Rev. Med. Chem. 2006, 6, 639-650 (Pubitemid 43881114)
51. Lemm, J. A.; OBoyle, D., II; Liu, M.; Nower, P. T.; Colonno, R.; Deshpande, M. S.; Snyder, L. B.; Martin, S. W.; St. Laurent, D. R.; Serrano-Wu, M. H.; Romine, J. L.; Meanwell, N. A; Gao, M. Identification of hepatitis C virus NS5A inhibitors J. Virol. 2010, 84, 482-491
52. Gao, M.; Nettles, R. E.; Belema, M.; Snyder, L. B.; Nguyen, V. N.; Fridell, R. A.; Serrano-Wu, M. H.; Langley, D. R.; Sun, J.-H.; OBoyle, D. R., II; Lemm, J. A.; Wang, C.; Knipe, J. O.; Chien, C.; Colonno, R. J.; Grasela, D. M.; Meanwell, N. A.; Hamann, L. G. Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect Nature 2010, 465, 96-102
53. Bell, T. W. Drugs for hepatitis C: unlocking a new mechanism of action ChemMedChem 2010, 210, 1663-1665